BrainStorm Cell Therapeutics Q2 Net Loss Widens - Quick Facts

(RTTNews) - BrainStorm Cell Therapeutics Inc. (BCLI), an Israel-based developer of adult stem cell technologies for neurodegenerative diseases, reported Tuesday that its second-quarter net loss widened to $1.04 million from last year's net loss of $962 thousand. Net loss per share was $0.06, compared to loss of $0.05 a year ago.

Research and development expenses, net were $435 thousand, higher than $151 thousand last year. General and administrative expenses declined to $640 thousand from $832 thousand a year ago.

At June 30, the Company had net working capital of $6.97 million including cash, cash equivalents and short-term bank deposits amounting to $6.72 million.